Predicting Cardiovascular Risk in Participants Treated With Tirzepatide in the SURPASS 1-5 Trials

被引：0
|
作者：
Wiese, Russell J.
Wang, Hui
Mody, Reema
Benneyworth, Brian D.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Diabetes (Type II); Cardiovascular Risk; Drugs; Prediction model; Clinical trials;
D O I：
10.1161/circ.148.suppl_1.16589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16589
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
    Min, Thinzar
    Bain, Stephen C.
    DIABETES THERAPY, 2021, 12 (01) : 143 - 157
  • [22] Effect of tirzepatide in GADA-positive individuals with type 2 diabetes: a post hoc analysis of the SURPASS 2-5 trials
    Buzzetti, R.
    Peters, A. L.
    Lee, C. J.
    Pavo, I.
    Liu, M.
    Paik, J. S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S312 - S312
  • [23] Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin-Pooled Subgroup Analysis of SURPASS-5 and-6
    Bajaj, Harpreet S.
    Billings, Liana K.
    Liu, Minzhi
    Levine, Joshua A.
    Rodriguez, Angel
    Patel, Hiren
    DIABETES, 2024, 73
  • [24] Tirzepatide improves amino acid profile in people with long-standing diabetes and increased cardiovascular risk in the SURPASS-4 trial
    Pirro, V.
    Lin, Y.
    Willency, J. A.
    Abadi, A.
    Wiese, R. J.
    Duffin, K. L.
    Pavo, I.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S313 - S314
  • [25] The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
    Thinzar Min
    Stephen C. Bain
    Diabetes Therapy, 2021, 12 : 143 - 157
  • [26] Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
    Pearson, Ewan
    Del Prato, Stefano
    Pavo, Imre
    Franco, Denise R.
    Yang, Zhengyu
    Wiese, Russell
    Kahn, Steven E.
    DIABETES, 2022, 71
  • [27] Predictors of achieving and sustaining glycaemic control and weight loss with tirzepatide in individuals with type 2 diabetes and increased cardiovascular risk (SURPASS-4)
    Kahn, S. E.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Zheng, J.
    Nicolay, C.
    Hemmingway, A.
    Wiese, R. J.
    Pearson, E. R.
    DIABETOLOGIA, 2024, 67 : S362 - S362
  • [28] Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants in SURMOUNT 1-2
    Thethi, Tina
    Kokkinos, Alexander
    McKean-Matthews, Missy
    Lee, Clare
    Neff, Lisa
    Mast, Casey
    Rodriguez, Angel
    Stefanski, Adam
    Bartee, Amy
    OBESITY, 2024, 32 : 34 - 34
  • [29] Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS
    Peters, Anne L.
    Buzzetti, Raffaella
    Lee, Clare J.
    Pavo, Imre
    Liu, Minzhi
    Karanikas, Chrisanthi A.
    Paik, Jim S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 110 (04): : e962 - e969
  • [30] Patient-reported outcomes in patients with type 2 diabetes treated with tirzepatide or placebo as an add-on to basal insulin (SURPASS-5)
    Yu, M.
    Boye, K.
    Huh, R.
    Patel, H.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 244 - 245
12345